Three-Month Posttreatment Prostate-Specific Antigen Level as a Biomarker of Treatment Response in Patients With Intermediate-Risk or High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy and Radiotherapy

Cancer - United States

doi 10.1002/cncr.31400